Eli Lilly’s experimental triple hormone receptor agonist, retatrutide, has recently captured significant attention within the medical and pharmaceutical communities following…
Read More
Eli Lilly’s Retatrutide Shows Unprecedented Weight Loss, But Increased Side Effects Raise Tolerability Concerns
Eli Lilly and Company’s investigational drug, retatrutide, a pioneering triple hormone receptor agonist, has demonstrated an average weight loss of…
Read More
The Potential Anticancer Effects of GLP-1 Receptor Agonists: A Promising Frontier, Yet Still Under Intense Scientific Scrutiny
SAN DIEGO – The rapidly expanding therapeutic landscape of glucagon-like peptide-1 (GLP-1) receptor agonists, widely recognized for their transformative impact…
Read More
GLP-1 Receptor Agonists and the Emerging Question of Anticancer Effects
The rapidly expanding landscape of drugs designed to mimic glucagon-like peptide-1 (GLP-1), famously exemplified by Ozempic and Wegovy, is increasingly…
Read More
Unlocking the Genetic Keys to GLP-1 Drug Efficacy and Side Effects
A groundbreaking study involving over 23andMe customers has identified genetic variations in two key genes that significantly influence both the…
Read More
Unlocking the Brain’s Secret Role in Metformin’s Anti-Diabetic Effects: A New Frontier in Metabolic Research
For more than six decades, metformin has served as the cornerstone of pharmacological management for type 2 diabetes. Since its…
Read More
Breakthrough Research Reveals the Brain as a Primary Driver of Metformin’s Anti-Diabetic Effects through Rap1 Signaling
For more than six decades, metformin has served as the foundational pharmacotherapy for the management of type 2 diabetes, a…
Read More
TWiV 1290: Clinical Update with Dr. Daniel Griffin Discusses Screwworm, Shingles Vaccine’s Anti-Aging Effects, and Current Public Health Data
In a recent clinical update featured on "This Week in Virology" (TWiV) episode 1290, Dr. Daniel Griffin provided a comprehensive…
Read MoreYOU MAY HAVE MISSED
